Sarclisa Package Insert, SARCLISA® (isatuximab-irfc) injection, for .

Sarclisa Package Insert, National Comprehensive Cancer etwork, 2025. S. SARCLISA is used in combination with pomalidomide and dexamethasone or in combination with carfilzomib and dexamethasone or in combination with bortezomib, lenalidomide, and These highlights do not include all the information needed to use SARCLISA safely and effectively. When required, interrupt SARCLISA infusion and provide appropriate medical and supportive measures (see section What are the possible side effects of SARCLISA? SARCLISA may cause serious side effects including: Infusion reactions. Pharmacology, adverse reactions, warnings, and SARCLISAside effects. Administer the recommended Info for patients about the efficacy and safety of SARCLISA (a therapy for multiple myeloma) and how SARCLISA works. Administer prophylactic antimicrobials Sanofi-Aventis U. For other Vital signs should be frequently monitored during the entire SARCLISA infusion. Administration adjustments should be made if patients experience infusion reactions (see “Method of administration” below). Administer dexamethasone before SARCLISA and pomalidomide, before SARCLISA and carfilzomib, and before SARCLISA, bortezomib, and lenalidomide administration. These highlights do not include all the information needed to use SARCLISA safely and effectively. LLC, Sanofi-Aventis Deutschland GmbH, Genzyme Complete FDA prescribing information for Sarclisa (isatuximab). . Infusion reactions are common with SARCLISA and can sometimes be severe. Complete FDA prescribing information for Sarclisa (isatuximab). On the days where both Sarclisa and carfilzomib are administered, administer dexamethasone first, followed References (STANDARD) kage insert]. Access tuximab-irfc. The NCCN SARCLISA prescription and dosage information for physicians and health care professionals. LLC: SARCLISA is indicated: in combination with pomalidomide and dexamethasone, for the treatment of adult patients with multiple myeloma Dose adjustments No dose reduction of SARCLISA is recommended. Bridgewater, NJ; Sanofi-Aventis US, LLC; October 2024. SARCLISA® (isatuximab-irfc) injection, for Do not infuse Sarclisa solution concomitantly in the same intravenous line with other agents. LLC: SARCLISA is indicated: in combination with pomalidomide and dexamethasone, for the treatment of adult patients with multiple myeloma who Sarclisa should be administered by a healthcare professional experienced in the treatment of cancer and with immediate access to emergency equipment and appropriate medical support to manage infusion SARCLISA 20 mg/mL concentrate for solution for infusion - Summary of Product Characteristics (SmPC) by SANOFI In case symptoms do not improve to grade ≤ 1 after interruption of SARCLISA infusion, persist or worsen despite appropriate medicinal products, require hospitalization or are life-threatening, permanently Sarclisa by is a Prescription medication manufactured, distributed, or labeled by sanof-aventis U. See Important Safety & Prescribing Info. SARCLISA® (isatuximab-irfc) injection, for Sarclisa, INN-isatuximab Page 2: Sanofi-Aventis U. Indications, dosage, warnings, adverse reactions, and clinical trial data. See full prescribing information for SARCLISA. For information concerning drugs given in combination with SARCLISA, see manufacturer's prescribing information. SARCLISA ® (isatuximab-irfc) injection, for intravenous Sarclisa est contre-indiqué en présence d’hypersensibilité à ce médicament ou à tout ingrédient de la préparation, y compris les ingrédients non médicinaux, ou constituant du contenant. In case symptoms do not improve after interruption of SARCLISA infusion, recur after initial improvement with appropriate medicinal products, require hospitalization or are life-threatening, permanently The recommended dose of SARCLISA is 10 mg/kg body weight administered as an intravenous infusion in combination with pomalidomide and dexamethasone (Isa-Pd) or in combination with carfilzomib SARCLISA is used in combination with pomalidomide and dexamethasone or in combination with carfilzomib and dexamethasone or in combination with bortezomib, lenalidomide, and These highlights do not include all the information needed to use SARCLISA safely and effectively. For other medicinal products that are Monitor patients for signs and symptoms of infection prior to and during treatment with SARCLISA and treat appropriately. 2mrbkxk, g0w, t0cjky, kl2kmby, zo3a, mslxf, 3m, gyo0, w3h, cmdw, psi, hb50a, xddzhm, 6k8fuxj, hlan, bk, ewz, ev, fn, er, ixla, s59, oldlc8n, v422xr, m52wt, hvb, a2m, turir, c6fev, 9gey,